The cystine/glutamate antiporter system xc- drives breast tumor cell glutamate release and cancer-induced bone pain.

ABSTRACT: Bone is one of the leading sites of metastasis for frequently diagnosed malignancies, including those arising in the breast, prostate and lung. Although these cancers develop unnoticed and are painless in their primary sites, bone metastases result in debilitating pain. Deeper investigation of this pain may reveal etiology and lead to early cancer detection. Cancer-induced bone pain (CIBP) is inadequately managed with current standard-of-care analgesics and dramatically diminishes patient quality of life. While CIBP etiology is multifaceted, elevated levels of glutamate, an excitatory neurotransmitter, in the bone-tumor microenvironment may drive maladaptive nociceptive signaling. Here, we establish a relationship between the reactive nitrogen species peroxynitrite, tumor-derived glutamate

SUBMITTER: Slosky LM 

PROVIDER: S-EPMC5065056 | biostudies-literature | 2016 Nov

REPOSITORIES: biostudies-literature